# A Study of the Safety, Tolerability and Effectiveness of Hydroxychloroquine and Itraconazole in Platinum-resistant Epithelial Ovarian Cancer

> **NCT03081702** · PHASE1,PHASE2 · COMPLETED · sponsor: **University Health Network, Toronto** · enrollment: 13 (actual)

## Conditions studied

- Platinum-resistant Epithelial Ovarian Cancer

## Interventions

- **DRUG:** Hydroxychloroquine
- **DRUG:** Itraconazole

## Key facts

- **NCT ID:** NCT03081702
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-25
- **Primary completion:** 2019-08-27
- **Final completion:** 2019-08-27
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2021-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03081702

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03081702, "A Study of the Safety, Tolerability and Effectiveness of Hydroxychloroquine and Itraconazole in Platinum-resistant Epithelial Ovarian Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03081702. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*